At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 22, 2026 at 06:00 ET
Repligen acquires BioLife Solutions for $1.5B (64% stock, 36% cash), paying $31.00/share, a 24% premium to the 90-day VWAP. The deal adds BioLife's high-margin biopreservation media franchise (CryoStor®) and expands Repligen's cell therapy exposure. Repligen also guided preliminary Q2 revenue growth of ~12% reported / 13% organic, while BioLife posted $28.5M in Q2 revenue (+21% YoY). The transaction is expected to close in Q4 2026 and be accretive to Repligen's EPS by at least $0.05 in year one and $0.25 in year two.
- Total enterprise value of approximately $1.5 billion (64% Repligen common stock, 36% cash)
- BioLife stockholders receive $11.25 cash + 0.1442 shares of Repligen common stock per share, total value $31.00/share
- Implied premium of 24% to 90-day VWAP ended July 21, 2026
- Transaction expected to close in Q4 2026, subject to regulatory approvals and BioLife stockholder approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access